MCCN Executes Extraction Agreement with Third-Party Cultivator
Bogota, Colombia--(Newsfile Corp. - June 8, 2021) - Medcolcanna Organics Inc. (TSXV: MCCN) (FSE: MO2) ("Medcolcanna", "MCCN" or the "Company"), a leading Canadian and globally integrated medicinal cannabis company with operations in Colombia, is pleased to announce the execution of a long-term commercial extraction services agreement with La Finca Interactiva Arachna Inc. SAS ("La Finca"). La Finca is a Colombian based whole-owned subsidiary of Chemesis International Inc (C.CSI). The agreement is for MCCN to provide extraction services for La Finca.
This executed commercial execution services agreement is the second such agreement that MCCN has entered into since launching its third-party commercial extraction services in May 2021. MCCN is pleased with execution of this second commercial extraction agreement and is encouraged with the interest that has been received from Colombian cultivators with the potential of providing third-party extraction services in Colombia.
MCCN is to initially provide extraction services to La Finca for 26,000 kilograms of dried biomass every three months. MCCN will immediately benefit by utilizing capacity of its 800 tons per year of dried biomass extraction capacity. This will allow MCCN to reduce its fixed extraction costs on a per unit basis which will be beneficial to all of MCCN's extraction customers as well as reduce the cost for MCCN to extract its own cultivated biomass.
MCCN will retain a portion of the isolates in exchange for the extraction services it provides. Conversely, Finca will receive a portion of the isolate in exchange for supplying the biomass. The portion that each party retains will depend on the potency of the desired cannabinoids present in the biomass. La Finca will deliver the non-psychoactive biomass to MCCN's extraction facility. This biomass will then be processed by MCCN, extracting the cannabinoid oils and/or isolates.
The execution of this agreement between Extralia Labs which is MCCN's 100% wholly owned subsidiary and La Finca is expected to generate additional revenue from the extraction services provided. MCCN believes that, with this additional revenue added to its current 3rd party extraction operations this will allow MCCN Extraction Services business unit to become approximately operationally self-sustaining, by the third quarter in 2021, and profitable by Q4. The first delivery is expected within the next 60-90 days and a detailed schedule on production will be submitted by La FINCA.
La Finca is a Colombian cultivation company and has been a wholly- owned subsidiary of Chemesis since January. 2019. and holds a license for the cultivation of non-psychoactive cannabis since 2007.
Additional Operational update
MCCN's Propagation business Unit has recently executed a new agreement to supply approximately 10,000 cuttings per month. The additional revenue that will be generated from agreement for cannabis plant cuttings, will bring MCCN's propagation business unit to approximate self-sustainability and with an outlook to profitability. Additionally, twenty-eight cutting supply agreements have been executed, the counter parties vary from licensed and operating companies to companies that are yet to receive their cultivation licenses.
MCCN is also pleased to provide an update on the export of its CBD Isolate product from its Colombia facilities as well as recent sales. MCCN has exported approximately 100 kilos of CBD isolate during the last 60-days all 100 kilos have been delivered to customers. MCCN is encouraged that, through its distribution, logistical process and procedures, it has been able to deliver these products to its valued customers. MCCN was also pleased that some of the recent sales are from recurring customer purchases.
Medcolcanna is a Canadian-integrated medical cannabis company, whose fully licensed operations are based in Colombia.
Led by a proven and successful management team, Medcolcanna has a growing number of facilities in optimal growing locations, which positions the Company to become a global leader in the medical cannabis market.
Medcolcanna employs state-of-the-art organic agricultural technology and innovative pharmaceutical processes to produce high-quality products.
The Company's scalable production model and network of pharmaceutical partnerships globally ensures that they remain at the forefront of the medical cannabis industry.
Additional information about Medcolcanna can be found on its web site at medcolcanna.com
Medcolcanna Investor Relations Contact:
Chris Reid, CFO Carrera 49b # 93-62 Bogota, Colombia
Phone: +571 642-9113
This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking statements") within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release.
Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as "expects", or "does not expect", "is expected", "anticipates" or "does not anticipate", "plans", "budget", "scheduled", "forecasts", "estimates", "believes" or "intends" or variations of such words and phrases or stating that certain actions, events or results "may", "could", "would", "might" or "will" be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements.
Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to general business, economic, competitive, political and social uncertainties; and the delay or failure to receive board, shareholder or regulatory approvals for any proposed transaction, including those discussed herein. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release.
Medcolcanna assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/86345